Paratek shares soar as antibiotic passes late-stage hurdle

Shares of Paratek Pharmaceuticals jumped in after-hours trading Monday after the Boston-based biotech said that its lead antibiotic drug had performed well in a Phase 3 study involving patients with hospital-acquired pneumonia. The news comes a week after reporting positive data from a late-stage trial of an acne treatment. Paratek (Nasdaq: PRTK) said the 774-patient study had showed that omadacycline was nearly as effective as another common antibiotic, moxifloxacin, in helping patients reduce…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news